Market capitalization | $1.86b |
Enterprise Value | $1.04b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.05 |
P/S ratio (TTM) P/S ratio | 1.89 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -38.17% |
Revenue (TTM) Revenue | $987.67m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
5 Analysts have issued a Novavax, Inc. forecast:
5 Analysts have issued a Novavax, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 988 988 |
38%
38%
|
|
Gross Profit | 655 655 |
27%
27%
|
|
EBITDA | -241 -241 |
58%
58%
|
EBIT (Operating Income) EBIT | -286 -286 |
53%
53%
|
Net Profit | -294 -294 |
50%
50%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Head office | United States |
CEO | John Jacobs |
Employees | 1,543 |
Founded | 1987 |
Website | www.novavax.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.